Smartlab Europe

Pharma Packaging Equipment Market to Reach $13.3B by 2033

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

SGD Pharma Advances Nasal Drug Delivery with Prince Deal

SGD Pharma has entered into a Franco-American OEM collaboration...

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.
- Advertisement -

Driven by the growing importance and rising demand for pharmaceutical packaging, the global pharmaceutical packaging equipment market is projected to reach approximately US$ 13.3 billion by 2033. This momentum is expected to open new opportunities for the sector, supporting a forecasted compound annual growth rate of 9.0% over the assessment period.

The pharmaceutical packaging sector happens to be seeing quite a substantial revolution by means of modern technological integration, consequently leading to better efficiency, exactness, and also standards in quality.

Automation and robots are crucial in this respect, simplifying packing procedures while at the same time decreasing human mistakes. These unique methods aid with precise and consistent packing, guaranteeing that every pharmaceutical unit has the proper and exact quantity of dose.

In totality, the cutting-edge technological essence is truly transforming pharmaceutical packaging and, in a manner, ushering in an age of rising dependability as well as consistency when it comes to the manufacturing process.

Major Takeaways That The Future Market Insights Report Offers

In terms of automation, the automated vertical will have a CAGR of 7.6% in 2033.

During the whole time of the prediction, it is very probable that the United States will have a compound annual growth rate (CAGR) of 7.6%.

As far as machine type is concerned, the blister packaging sector is the one that is most expected to dominate the market by means of a compound annual growth rate of 5% in the year 2033.

It is expected that the value of the market for pharmaceutical packaging equipment would reach more than $13.3 billion by the year 2033.

Over the forecast period ending in 2033, the pharmaceutical packaging equipment market is expected to expand at a 9.0% CAGR.

Specifically, the rise of generic medications around the world is a significant element that is most likely to accelerate the development of the pharmaceutical packaging equipment market in the near future.

Latest stories

Related stories

SGD Pharma Advances Nasal Drug Delivery with Prince Deal

SGD Pharma has entered into a Franco-American OEM collaboration...

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »